Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates.
Published: 2026-12-01
mAbs
MediLens Indexed: 2026-05-23
This study investigates the safety and tolerability of Procizumab (PCZ), an antibody that antagonizes circulating dipeptidyl peptidase 3 (cDPP3), which is released during cellular stress and impacts vascular tone. The findings may have implications for resuscitation strategies in shock management.
Read on PubMed